GECAT - German Evaluation of Cancer associated Thrombosis: A Prospective Register Trial for Patients with Active Cancer and Venous Thromboembolism in Berlin

M. Sinn; C. Pollich; S. Bischoff; E. Wolters; E. Späth-Schwalbe; C. Leng; M. de Wit; P. Habbel; C.W. Scholz; A. Jühling; L. Wislocka; M. Orlovic; H. Riess; R. Klamroth

doi:10.1055/s-0039-1680127

Hämostaseologie, Table of Contents

Hamostaseologie 2019; 39(S 01): S1-S92
DOI: 10.1055/s-0039-1680127

SY14 Cancer and Thrombosis

Georg Thieme Verlag KG Stuttgart · New York

GECAT - German Evaluation of Cancer associated Thrombosis: A Prospective Register Trial for Patients with Active Cancer and Venous Thromboembolism in Berlin

M. Sinn

¹Hematology, Medical Oncology and Tumorimmunology CVK, Charité - University Medicine Berlin, Berlin, Germany

,

C. Pollich

²Department of Haemophilia and Haemostasis, Vivantes Hospital in Friedrichshain, Berlin, Germany

,

S. Bischoff

¹Hematology, Medical Oncology and Tumorimmunology CVK, Charité - University Medicine Berlin, Berlin, Germany

,

E. Wolters

¹Hematology, Medical Oncology and Tumorimmunology CVK, Charité - University Medicine Berlin, Berlin, Germany

,

E. Späth-Schwalbe

³Haematology, Medical Oncology and Palliative Care, Vivantes Hospital Spandau, Berlin, Germany

,

C. Leng

⁴Hematology and Medical Oncology CBF, Charité - University Medicine Berlin, Berlin, Germany

,

M. de Wit

⁵Department of Haematology, Medical Oncology and Palliative Care, Vivantes Hospital Neukoelln, Berlin, Germany

,

P. Habbel

⁶Department of Haematology and Medical Oncology CCM, Charité - University Medicine Berlin, Berlin, Germany

,

C.W. Scholz

⁷Department of Haematology and Medical Oncology, Vivantes Hospital by the Urban, Berlin, Germany

,

A. Jühling

¹Hematology, Medical Oncology and Tumorimmunology CVK, Charité - University Medicine Berlin, Berlin, Germany

⁸Department of Internal Medicine I - Medical Oncology, Haematology, Clinical Infectiology, Clinical Immunology, Haemostaseology, and Intensive Care, University Hospital Köln, Köln, Germany

,

L. Wislocka

¹Hematology, Medical Oncology and Tumorimmunology CVK, Charité - University Medicine Berlin, Berlin, Germany

,

M. Orlovic

²Department of Haemophilia and Haemostasis, Vivantes Hospital in Friedrichshain, Berlin, Germany

,

H. Riess

¹Hematology, Medical Oncology and Tumorimmunology CVK, Charité - University Medicine Berlin, Berlin, Germany

⁶Department of Haematology and Medical Oncology CCM, Charité - University Medicine Berlin, Berlin, Germany

,

R. Klamroth

²Department of Haemophilia and Haemostasis, Vivantes Hospital in Friedrichshain, Berlin, Germany

› Author Affiliations

Abstract

Full Text

Objectives: There are miscellaneous treatment recommendations for cancer patients (pts) with venous thromboembolism (VTE). Data about daily clinical practice of those patients in Germany are lacking.

Methods: The GECAT register was set up for Berlin´s two main hospital companies Charite-Universitaetsmedizin Berlin and Vivantes to document prospectively cancer patients with newly diagnosed VTE. Follow-ups were scheduled after 3 and 6 months via phone interview. The primary objective of this health service research study was to evaluate the treatment reality of patients suffering from cancer associated VTE in daily clinical practice. Main points of interest were diagnostics, anti-coagulation treatment and kind of cancer type as well as VTE localisation and severity.

Results: Between May 2015 and May 2017, 384 patients diagnosed with active cancer within the past 2 years and newly diagnosed VTE gave consent for inclusion in this register trial. 195 (51%) were female, 189 (49%) male, median age was 66 years (range 19–89). For 133 pts (35%), VTE was the primary reason for hospital admission, whereas 131 pts (35%) were transferred to one of the study sites by a medical oncologist, 118 pts (30%) via an emergency department and 52 pts (14%) by a general practitioner.

While 116 pts (30%) had isolated pulmonary embolism (PE), 69 (18%) had PE in and deep vein thrombosis (DVT) (including VTE of upper limb with or without catheter association, abdominal and cerebral veins) whereas 196 (51%) suffered from isolated DVT. In the vast majority of pts (n = 336, 88%), initial treatment was started with low-molecular-weight heparin (LMWH). 251 pts (56%) presented with stage IV cancer diseases, the most common cancer sites were lung (n = 49, 13%), gynecological (n = 44, 11%) and colorectal (n = 38, 10%). 281 pts (73%) received anticancer treatments at the time of diagnosis of VTE.

Conclusions: The GECAT trial provides new and clinically relevant information about the daily clinical practice of cancer patients with newly diagnosed VTE in Berlin.

Trial registration: The study was approved by the local ethic committee “Aerztekammer Berlin” (01–2015) and registered in the German registry for clinical studies (DRKS00008196).